Seres Therapeutics (MCRB) Accumulated Depreciation (2014 - 2026)

Seres Therapeutics has reported Accumulated Depreciation for 13 years, with the latest figure at $57.4 million in Q1 2026.

• Quarterly Accumulated Depreciation rose 5.75% year-over-year to $57.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.4 million (up 5.75% YoY) and the FY2025 annual result came in at $56.6 million, up 6.42% from the prior year.
• Accumulated Depreciation advanced to $57.4 million in Q1 2026 per MCRB's latest filing, from $56.6 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $57.4 million in Q1 2026 and troughed at $41.8 million in Q1 2022.
• A 5-year average of $50.6 million and a median of $52.2 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2022 and 2025: Accumulated Depreciation climbed 16.93% in 2022, then increased 2.82% in 2025.
• Over 5 years, Accumulated Depreciation stood at $45.0 million in 2022, then grew by 8.97% to $49.1 million in 2023, then gained by 8.39% to $53.2 million in 2024, then advanced by 6.42% to $56.6 million in 2025, then gained by 1.38% to $57.4 million in 2026.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $57.4 million, $56.6 million, and $56.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.